查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552548

獨立國協胰島素市場規模、佔有率、趨勢分析報告：按產品類型、按應用、按分銷管道、按地區、按細分市場、預測，2024-2030 年

CIS Insulin Market Size, Share & Trends Analysis Report By Product, By Type (Human Insulin, Insulin Analog), By Application (Type 1 Diabetes), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

獨立國協胰島素市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計2030年獨立國協胰島素市場規模將達到46.7億美元，2024年至2030年複合年成長率為5.6%。

憑藉廣泛的產品組合在未來六年內表現出更高的效力和商業化，該市場預計將成為一個有影響力的渲染驅動力。政府採取旨在透過降價提高胰島素負擔能力的舉措，可以對需求產生積極影響，正如 2013 年烏克蘭政府和 Indar 合作將胰島素價格降低 20% 預計會產生影響一樣。該市場的其他促進因素包括製造商擴大利用開拓的機會，開設新的生產設施來改善胰島素的供應，以及二型糖尿病患病率的增加，這預計將成為推動未來市場成長的一個因素。

CIS 胰島素市場報告亮點

  • 由於市場促進因素、限制因素、機會因素和威脅因素等影響市場成長的各種因素，波蘭獨立國協胰島素市場在 2023 年獲得了 10.3% 的顯著市場佔有率。
  • 長效胰島素佔市場主導地位，2023年佔52.7%的佔有率。長效胰島素模仿天然胰島素，起效較慢，主要作為基礎胰島素。
  • 1 型糖尿病佔據市場主導地位，2023 年佔 79.6% 的佔有率。 1 型糖尿病主要影響兒童、青少年和一些成年人。由於獨立國協地區盛行率不斷上升，預計 2 型糖尿病在預測期內的複合年成長率將達到 11.6%。
  • 2023 年，胰島素類似物以 89.0% 的最大銷售佔有率引領市場。胰島素類似物是一種人工胰島素，可以快速起效並對身體功能產生即時的效果。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 CIS 胰島素市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • CIS 胰島素市場分析工具
    • 波特的分析
    • PESTEL分析

第 4 章 CIS 胰島素市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 獨立國協胰島素市場：產品變化分析，百萬美元，2023 年和 2030 年
  • 速效胰島素
  • 長效胰島素
  • 複合胰島素
  • 生物相似藥
  • 其他

第5章 獨立國協胰島素市場：按類型估計和趨勢分析

  • 細分儀表板
  • 獨立國協胰島素市場：類型變異分析，百萬美元，2023 年和 2030 年
  • 人類胰島素
  • 胰島素類似物

第6章 CIS 胰島素市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 獨立國協胰島素市場：應用變化分析，百萬美元，2023 年和 2030 年
  • 1型糖尿病
  • 2型糖尿病

第 7 章 獨立國協胰島素市場：按分銷管道的估計和趨勢分析

  • 細分儀表板
  • 獨立國協胰島素市場：分銷管道變化分析，百萬美元，2023 年和 2030 年
  • 醫院藥房
  • 零售/專業藥房
  • 其他

第 8 章 獨立國協胰島素市場：區域、估計與趨勢分析

  • 2023 年及 2030 年獨立國協胰島素市場佔有率（按地區），百萬美元
  • 獨立國協(CIS)
    • 俄羅斯
    • 波蘭
    • 土耳其
    • 烏克蘭
    • 烏茲別克
    • 白俄羅斯
    • 哈薩克
    • 其他獨立國協國家

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Eli Lilly and Company
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Oramed Pharmaceuticals Inc.
    • Novo Nordisk A/S
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
簡介目錄
Product Code: 978-1-68038-170-2

CIS Insulin Market Growth & Trends:

The CIS insulin market size is expected to reach USD 4.67 billion by 2030, registering a CAGR of 5.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

CIS Insulin Market Report Highlights:

  • Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats
  • Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins.
  • Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region.
  • Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body's functions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. CIS Insulin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. CIS Insulin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. CIS Insulin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. CIS Insulin Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Rapid-acting Insulin
    • 4.3.1. Rapid-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Long-acting Insulin
    • 4.4.1. Long-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Combination Insulin
    • 4.5.1. Combination Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Biosimilar
    • 4.6.1. Biosimilar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Other Products
    • 4.7.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. CIS Insulin Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. CIS Insulin Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Human Insulin
    • 5.3.1. Human Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Insulin Analog
    • 5.4.1. Insulin Analog Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. CIS Insulin Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. CIS Insulin Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Type I Diabetes
    • 6.3.1. Type I Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Type II Diabetes
    • 6.4.1. Type II Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. CIS Insulin Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. CIS Insulin Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail & Specialty Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Distribution Channels
    • 7.5.1. Other Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. CIS Insulin Market: Regional Estimates & Trend Analysis

  • 8.1. CIS Insulin Market Share, By Region, 2023 & 2030, USD Million
  • 8.2. Commonwealth of Independent States (CIS)
    • 8.2.1. CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. Russia
      • 8.2.2.1. Russia CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Poland
      • 8.2.3.1. Poland CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Turkey
      • 8.2.4.1. Turkey CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.5. Ukraine
      • 8.2.5.1. Ukraine CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.6. Uzbekistan
      • 8.2.6.1. Uzbekistan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.7. Belarus
      • 8.2.7.1. Belarus CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.8. Kazakhstan
      • 8.2.8.1. Kazakhstan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.9. Rest of CIS
      • 8.2.9.1. Rest of CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Eli Lilly and Company
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/Strategic Initiatives
    • 9.4.2. Sanofi S.A.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/Strategic Initiatives
    • 9.4.3. Boehringer Ingelheim International GmbH
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/Strategic Initiatives
    • 9.4.4. Oramed Pharmaceuticals Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/Strategic Initiatives
    • 9.4.5. Novo Nordisk A/S
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/Strategic Initiatives
    • 9.4.6. Merck & Co., Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/Strategic Initiatives
    • 9.4.7. Bristol-Myers Squibb Company
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/Strategic Initiatives
    • 9.4.8. Novartis AG
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/Strategic Initiatives